Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
Clinical trial NCT04886271 · COMPLETED
Trial details
- NCT number
- NCT04886271
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-12
- Primary completion
- 2024-01-12
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.